Multiple Risk Factors in Cardiovascular Disease: Medical Science Symposia Series, cartea 1
Maurizio Soma Editat de Antonio M. Gotto Jr., Claude Lenfant, Rodolfo Paolettien Limba Engleză Paperback – 11 aug 2012
Din seria Medical Science Symposia Series
- 5% Preț: 391.79 lei
- 5% Preț: 657.90 lei
- 5% Preț: 373.12 lei
- 5% Preț: 658.63 lei
- 5% Preț: 374.05 lei
- 5% Preț: 1102.67 lei
- 5% Preț: 646.58 lei
- 5% Preț: 359.98 lei
- 5% Preț: 777.55 lei
- 5% Preț: 707.69 lei
- 18% Preț: 948.92 lei
- 5% Preț: 1111.26 lei
- 15% Preț: 641.38 lei
- 5% Preț: 382.26 lei
- 5% Preț: 375.13 lei
- 5% Preț: 711.15 lei
- 5% Preț: 1426.33 lei
- 5% Preț: 1408.60 lei
- Preț: 386.99 lei
- 5% Preț: 377.52 lei
- 5% Preț: 1101.21 lei
Preț: 368.37 lei
Preț vechi: 387.75 lei
-5% Nou
Puncte Express: 553
Preț estimativ în valută:
70.50€ • 72.98$ • 59.59£
70.50€ • 72.98$ • 59.59£
Carte tipărită la comandă
Livrare economică 05-19 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9789401051965
ISBN-10: 9401051968
Pagini: 288
Ilustrații: XVI, 268 p. 23 illus.
Dimensiuni: 160 x 240 x 15 mm
Greutate: 0.41 kg
Ediția:Softcover reprint of the original 1st ed. 1992
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Medical Science Symposia Series
Locul publicării:Dordrecht, Netherlands
ISBN-10: 9401051968
Pagini: 288
Ilustrații: XVI, 268 p. 23 illus.
Dimensiuni: 160 x 240 x 15 mm
Greutate: 0.41 kg
Ediția:Softcover reprint of the original 1st ed. 1992
Editura: SPRINGER NETHERLANDS
Colecția Springer
Seria Medical Science Symposia Series
Locul publicării:Dordrecht, Netherlands
Public țintă
ResearchCuprins
1. Individual risk factors for cardiovascular disease.- 2. The lipid hypothesis: is it the only cause of atherosclerosis?.- 3. Life styles and life style related major risk factors: their combined impact in producing epidemic cardiovascular disease, and the potential for prevention.- 4. The role of genetics as a risk factor in cardiovascular disease.- 5. Multiple risk factors in an Italian population in the 1980’s: the Gubbio study.- 6. Cardiovascular risk factors in older individuals.- 7. Retardation and regression of coronary atherosclerosis: fact or fiction?.- 8. Cardiovascular risk factors and intervention in children.- 9. Should (nearly) every postmenopausal woman be treated with estrogen to prevent heart disease?.- 10. Role of insulin resistance in human disease.- 11. The effects of insulin on the cardiovascular system.- 12. Insulin — a risk factor for cardiovascular disease?.- 13. Hypertension and dyslipidemia in high risk families.- 14. Hypertension and aging induce similar changes in molecular, cellular, and connective tissue responses of the arterial wall.- 15. Plasma renin as a risk factor for heart attack and stroke in hypertension.- 16. Cardiovascular risk factor profile of hypertension: therapeutic approaches.- 17. Specific antihypertensive therapy: an achievable goal?.- 18. Effects of blood pressure control on the prevention of cardiovascular complications in older hypertensives.- 19. Calcium channel blockade and coronary vasomotility in hypertension.- 20. Antihypertensive agents and cardiovascular risk.- 21. Hypertension and atherosclerosis: role of calcium antagonists as antiatherogenic agents with an emphasis on clinical trials.- 22. Stepped-care versus individualized antihypertensive treatment in the 1990’s.- 23. Body fat distribution andcardiovascular disease.- 24. Lipoprotein(a) as an athero-antifibrinolytic risk factor.- 25. Aspirin in the secondary prevention of cardiovascular disease.- 26. Interactions of atherogenic lipoproteins with endothelium and blood cells.- 27. Left ventricular mass as a measure of preclinical disease in patients with hypertension.- 28. Increased triglyceride levels and cardiovascular disease.- 29. Whither triglycerides in the cholesterol campaign.- 30. Plasma triglyceride and coronary heart disease.- 31. Role of high density lipoprotein in plasma lipid transport: is cholesterol efflux from cells coupled to lipolysis of triglyceride-rich lipoproteins?.- 32. Non-pharmacological measures to improve HDL-cholesterol and plasma triglyceride levels.- 33. Drugs affecting HDL/triglyceride levels.- 34. Fibrates and reversal of atherogenic particles.- 35. HDL cholesterol: methodological considerations and laboratory performance.